Genentech Reports Results of Port Delivery System with Ranibizumab in P-III Archway Study for Neovascular Age-Related Macular Degeneration

July 23, 2020 Auto Bot Biotech, Genentech, Latest, Neovascular Age-Related Macular Degeneration, P-III, ranibizumab, reports, results 0

Shots:

  • The P-III Archway study involves assessing of PDS with ranibizumab, refilled @6mos. at fixed intervals, vs ranibizumab (0.5mg, monthly IVT) in 418 patients with nAMD, prior treated with VEGF therapy
  • Results: 98.4% of PDS patients were able to go 6mos. without needing additional treatment and achieved vision outcomes equivalent to patients receiving ranibizumab (0.5mg, monthly IVT), PDS demonstrated non-inferior and equivalent visual acuity outcomes with a favorable benefit-risk profile
  • PDS is a permanent refillable eye implant that continuously delivers a customized formulation of ranibizumab over a period of mos., potentially reducing the treatment burden associated with frequent eye injections

Click here to read full press release/ article | Ref: Genentech | Image: Twitter